Dermapharm Holding SE reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was EUR 266.41 million compared to EUR 242.88 million a year ago. Net loss was EUR 9.19 million compared to net income of EUR 14.52 million a year ago. Basic loss per share from continuing operations was EUR 0.17 compared to basic earnings per share from continuing operations of EUR 0.27 a year ago.
For the six months, sales was EUR 589.27 million compared to EUR 478.61 million a year ago. Net income was EUR 40.22 million compared to EUR 51.89 million a year ago. Basic earnings per share from continuing operations was EUR 0.75 compared to EUR 0.96 a year ago.